{"id":"rapamune-sirolimus","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Hyperlipidemia"},{"rate":"15-30","effect":"Thrombocytopenia"},{"rate":"20-30","effect":"Anemia"},{"rate":"20-30","effect":"Hypertension"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"15-20","effect":"Headache"},{"rate":"10-20","effect":"Arthralgia"},{"rate":"10-15","effect":"Acne"},{"rate":"10-15","effect":"Impaired wound healing"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sirolimus binds to FKBP12 and the resulting complex inhibits mTOR kinase, which is essential for T-cell and B-cell proliferation. By blocking mTOR, the drug prevents the progression of lymphocytes from the G1 to S phase of the cell cycle, effectively suppressing the immune response. This mechanism makes it particularly useful in preventing organ transplant rejection and treating certain proliferative diseases.","oneSentence":"Sirolimus inhibits mTOR (mammalian target of rapamycin), a key signaling protein that controls cell growth and proliferation, thereby suppressing immune cell activation and reducing organ rejection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:58.847Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis of organ rejection in patients receiving renal transplants"},{"name":"Lymphangioleiomyomatosis (LAM)"}]},"trialDetails":[{"nctId":"NCT07190690","phase":"NA","title":"Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions","status":"RECRUITING","sponsor":"Fundación EPIC","startDate":"2025-12-19","conditions":"Coronary Artery Disease","enrollment":2100},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":4200},{"nctId":"NCT04802759","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-22","conditions":"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer","enrollment":316},{"nctId":"NCT06863155","phase":"","title":"Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation","status":"RECRUITING","sponsor":"Fundación EPIC","startDate":"2025-05-06","conditions":"Coronary Artery Disease, Ischemic Heart Disease","enrollment":500},{"nctId":"NCT07444957","phase":"","title":"Safety and Effectiveness of the Crystalline Sirolimus-Eluting Device in Patients With Coronary Artery Disease","status":"RECRUITING","sponsor":"Fundación Interhospitalaria para la Investigación Cardiovascular FIC","startDate":"2026-01-05","conditions":"Coronary Arterial Disease (CAD), NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI), Stable Angina, Unstable Angina, NSTEMI","enrollment":1118},{"nctId":"NCT06055608","phase":"PHASE2","title":"Advancing Transplantation Outcomes in Children","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-05-22","conditions":"Kidney Transplant","enrollment":200},{"nctId":"NCT06308419","phase":"PHASE1","title":"A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-08-14","conditions":"Leiomyosarcoma, Soft-tissue Sarcomas","enrollment":18},{"nctId":"NCT05193565","phase":"PHASE4","title":"Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-11-19","conditions":"Kidney Transplantation","enrollment":206},{"nctId":"NCT04899141","phase":"","title":"Prospective Registry of ihtDEStiny® Coronary Stent in Regular PCI Practice","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación EPIC","startDate":"2021-10-29","conditions":"Coronary Artery Disease, Ischemic Heart Disease","enrollment":400},{"nctId":"NCT03504241","phase":"PHASE1","title":"Tolerance by Engaging Antigen During Cellular Homeostasis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-30","conditions":"Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient","enrollment":8},{"nctId":"NCT03972592","phase":"PHASE2","title":"Topical Sirolimus in Cutaneous Lymphatic Malformations","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2019-06-05","conditions":"Vascular Malformations, Lymphatic Malformation","enrollment":55},{"nctId":"NCT06075368","phase":"","title":"Efficacy and Safety of GENOSS® SES in Patients With Acute Coronary Syndrome (GENOSS ACS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genoss Co., Ltd.","startDate":"2020-03-16","conditions":"Acute Coronary Syndrome, Percutaneous Coronary Intervention","enrollment":757},{"nctId":"NCT02143726","phase":"PHASE2","title":"Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2014-10-09","conditions":"Refractory Hurthle Cell Thyroid Cancer","enrollment":35},{"nctId":"NCT07378657","phase":"PHASE3","title":"Systematic Approach for Children With Orbital Malformation With Sirolimus Use","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-11-01","conditions":"Orbital Lymphatic Malformation","enrollment":30},{"nctId":"NCT02081755","phase":"PHASE4","title":"Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Baylor Research Institute","startDate":"2014-03","conditions":"Carcinoma, Hepatocellular","enrollment":336},{"nctId":"NCT03121001","phase":"PHASE2","title":"Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2017-03-20","conditions":"Sickle Cell Disease","enrollment":50},{"nctId":"NCT07366801","phase":"PHASE2, PHASE3","title":"Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2025-09-03","conditions":"Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk, Acute Myeloid Leukemia, High Risk","enrollment":64},{"nctId":"NCT07354620","phase":"EARLY_PHASE1","title":"A Pilot Study on Reverse Aging (The REVERSE Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Christ Hospital","startDate":"2025-02-15","conditions":"Aging","enrollment":52},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT03284957","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2017-09-20","conditions":"Breast Cancer","enrollment":136},{"nctId":"NCT06973668","phase":"PHASE2","title":"A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-07-22","conditions":"AML","enrollment":80},{"nctId":"NCT05540223","phase":"NA","title":"Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System","status":"RECRUITING","sponsor":"Biotronik AG","startDate":"2024-05-13","conditions":"Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia","enrollment":1859},{"nctId":"NCT00600496","phase":"PHASE1","title":"A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2007-12-14","conditions":"Breast Cancer, Breast Neoplasms, Colon Cancer","enrollment":140},{"nctId":"NCT07045194","phase":"NA","title":"Virtue® SAB in the Treatment of Coronary ISR Trial","status":"RECRUITING","sponsor":"Orchestra BioMed, Inc","startDate":"2025-10-20","conditions":"Coronary Artery Disease","enrollment":740},{"nctId":"NCT05508906","phase":"PHASE1","title":"Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer","status":"RECRUITING","sponsor":"Olema Pharmaceuticals, Inc.","startDate":"2022-08-31","conditions":"Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":190},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT06168305","phase":"","title":"Safety and Effectiveness of GENOSS® DES in Patients With Multivessel Coronary Artery Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Genoss Co., Ltd.","startDate":"2023-11-15","conditions":"Percutaneous Coronary Intervention, Multivessel Coronary Artery Disease","enrollment":1000},{"nctId":"NCT06086496","phase":"","title":"Effectiveness and Safety of Abluminal Biodegradable Polymer Sirolimus-eluting Stent (GENOSS® DES)","status":"ENROLLING_BY_INVITATION","sponsor":"Genoss Co., Ltd.","startDate":"2022-07-15","conditions":"Coronary Artery Disease, Percutaneous Coronary Intervention","enrollment":1000},{"nctId":"NCT06680921","phase":"PHASE3","title":"A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)","status":"RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2024-11-14","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":460},{"nctId":"NCT06822712","phase":"NA","title":"Efficacy and Safety of Sirolimus-coated Coronary Balloon Dilatation Catheter for De Novo Coronary Bifurcation Lesions","status":"RECRUITING","sponsor":"BrosMed Medical Co., Ltd","startDate":"2025-03-03","conditions":"Coronary Arterial Disease (CAD)","enrollment":250},{"nctId":"NCT06326190","phase":"PHASE2","title":"177Lu-DOTATATE for Recurrent Meningioma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-03-10","conditions":"Recurrent Meningioma","enrollment":136},{"nctId":"NCT07159087","phase":"NA","title":"The Safety and Efficacy for In-segment Late Lumen Loss of the 'Genoss® SCB' Versus 'SeQuent® Please NEO' in Patients With Coronary ISR","status":"ENROLLING_BY_INVITATION","sponsor":"Genoss Co., Ltd.","startDate":"2025-02-19","conditions":"Coronary Arterial Disease (CAD)","enrollment":94},{"nctId":"NCT03240731","phase":"PHASE2","title":"HLA Haploidentical Bone Marrow Transplant in Patients With Severe Sickle Cell Disease","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2017-08-10","conditions":"Sickle Cell Disease","enrollment":25},{"nctId":"NCT02790515","phase":"PHASE2","title":"Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-07-14","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma","enrollment":170},{"nctId":"NCT02793544","phase":"PHASE2","title":"HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide","status":"COMPLETED","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2016-12","conditions":"Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma","enrollment":80},{"nctId":"NCT04473911","phase":"PHASE1","title":"Haplo Peripheral Blood Sct In GVHD Prevention","status":"COMPLETED","sponsor":"Zachariah Michael DeFilipp","startDate":"2020-08-14","conditions":"GVHD, AML, ALL","enrollment":25},{"nctId":"NCT05719883","phase":"NA","title":"Evaluating the Safety and Efficacy of the Maurora® DES in ICAS","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2023-02-20","conditions":"Intracranial Arteriosclerosis, Stroke (CVA) or TIA","enrollment":156},{"nctId":"NCT06802055","phase":"PHASE2","title":"Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-01-25","conditions":"Aplastic Anaemia","enrollment":40},{"nctId":"NCT03049189","phase":"PHASE3","title":"Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2017-02-02","conditions":"Neuroendocrine Tumors","enrollment":309},{"nctId":"NCT03660930","phase":"PHASE1, PHASE2","title":"Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas","status":"TERMINATED","sponsor":"University of Washington","startDate":"2019-04-01","conditions":"Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma","enrollment":19},{"nctId":"NCT03263559","phase":"PHASE2","title":"Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-10-03","conditions":"Sickle Cell Disease","enrollment":95},{"nctId":"NCT06942156","phase":"PHASE4","title":"Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2025-08-14","conditions":"Heart Transplant","enrollment":140},{"nctId":"NCT03324373","phase":"PHASE1","title":"Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)","status":"COMPLETED","sponsor":"Yousef Zakharia","startDate":"2019-03-20","conditions":"Renal Cell Carcinoma","enrollment":11},{"nctId":"NCT02766465","phase":"PHASE2","title":"Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-03-16","conditions":"Sickle Cell Disease","enrollment":138},{"nctId":"NCT06925971","phase":"PHASE3","title":"A Randomized Trial of the Rapamycin Target Eluting Stent for the Treatment of Symptomatic Cerebral Artery Atherosclerotic Disease（TARGET-DREAM）","status":"NOT_YET_RECRUITING","sponsor":"MicroPort NeuroTech Co., Ltd.","startDate":"2025-04-15","conditions":"Intracranial Arteriosclerosis","enrollment":279},{"nctId":"NCT06914089","phase":"NA","title":"Thin Versus Thicker Strut Thickness Stents in Primary Percutaneous Intervention","status":"COMPLETED","sponsor":"Assiut University","startDate":"2020-10-01","conditions":"Primary Percutaneous Coronary Intervention","enrollment":146},{"nctId":"NCT05773326","phase":"EARLY_PHASE1","title":"Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG","status":"RECRUITING","sponsor":"Nader Sanai","startDate":"2023-05-15","conditions":"High Grade Glioma, Glioma, Glioma, Malignant","enrollment":12},{"nctId":"NCT06075433","phase":"","title":"Efficacy and Safety of 1-year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-risk Procedure","status":"RECRUITING","sponsor":"Genoss Co., Ltd.","startDate":"2022-05-13","conditions":"Coronary Artery Disease, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy","enrollment":1000},{"nctId":"NCT06075420","phase":"","title":"Efficacy and Safety of Short Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease","status":"RECRUITING","sponsor":"Genoss Co., Ltd.","startDate":"2021-08-18","conditions":"Percutaneous Coronary Intervention, Dual Antiplatelet Therapy","enrollment":1000},{"nctId":"NCT06066476","phase":"","title":"Efficacy and Safety of GENOSS® DES in Patients with Coronary Artery Disease","status":"COMPLETED","sponsor":"Genoss Co., Ltd.","startDate":"2017-06-24","conditions":"Coronary Artery Disease","enrollment":1022},{"nctId":"NCT02531932","phase":"PHASE2","title":"Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Amy Tiersten","startDate":"2015-12-16","conditions":"Breast Cancer","enrollment":64},{"nctId":"NCT03190174","phase":"PHASE1, PHASE2","title":"Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers","status":"COMPLETED","sponsor":"Sarcoma Oncology Research Center, LLC","startDate":"2017-08-24","conditions":"Ewing Sarcoma, PEComa, Epithelioid Sarcoma","enrollment":34},{"nctId":"NCT06504225","phase":"","title":"EVEROLD LONG TERM FOLLOW-UP","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2024-08-23","conditions":"Transplant; Complication, Failure","enrollment":260},{"nctId":"NCT06789900","phase":"PHASE2","title":"Everolimus and/or Exercise to Prevent Bone Loss in Postmenopausal Women","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2024-10-14","conditions":"Postmenopausal Women","enrollment":136},{"nctId":"NCT04470934","phase":"","title":"SeQuent® SCB \"All Comers\" Post Market Clinical Follow-up (PMCF)","status":"ACTIVE_NOT_RECRUITING","sponsor":"B. Braun Melsungen AG","startDate":"2021-04-30","conditions":"Coronary Artery Disease, Myocardial Ischaemia","enrollment":1302},{"nctId":"NCT03577431","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at MGH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-29","conditions":"Liver Transplant","enrollment":9},{"nctId":"NCT04948749","phase":"NA","title":"Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2021-07-02","conditions":"ICAD - Intracranial Atherosclerotic Disease, ICAS - Intracranial Atherosclerosis, Drug-eluting Stent","enrollment":792},{"nctId":"NCT01363752","phase":"PHASE4","title":"A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-03-08","conditions":"Kidney Transplantation","enrollment":853},{"nctId":"NCT00679042","phase":"PHASE3","title":"Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"CellTrans Inc.","startDate":"2007-09-05","conditions":"Type 1 Diabetes Mellitus","enrollment":21},{"nctId":"NCT04066114","phase":"PHASE1, PHASE2","title":"Treg Modulation With CD28 and IL-6 Receptor Antagonists","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-11","conditions":"Living-Donor Kidney Transplant, Kidney Transplant Recipients","enrollment":24},{"nctId":"NCT06618248","phase":"NA","title":"Efficacy and Safety of Sirolimus-Coated Spiral Balloon for Coronary Bifurcation Lesions","status":"RECRUITING","sponsor":"Dongguan TT Medical","startDate":"2023-12-20","conditions":"Coronary Bifurcation Lesion","enrollment":280},{"nctId":"NCT02228681","phase":"PHASE2","title":"Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer","status":"COMPLETED","sponsor":"GOG Foundation","startDate":"2015-05-21","conditions":"Advanced, Persistent, or Recurrent Endometrial Cancer","enrollment":74},{"nctId":"NCT02061800","phase":"PHASE1, PHASE2","title":"CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diane George","startDate":"2013-06-03","conditions":"Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)","enrollment":14},{"nctId":"NCT02155920","phase":"PHASE2","title":"Everolimus for Children With Recurrent or Progressive Ependymoma","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2015-02","conditions":"Recurrent Childhood Ependymoma","enrollment":11},{"nctId":"NCT03654040","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at UCSF","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":"Liver Transplant","enrollment":42},{"nctId":"NCT03908450","phase":"NA","title":"Treatment of Coronary De-novo Stenosis by a Sirolimus Coated Balloon or a Paclitaxel Coated Balloon Catheter","status":"COMPLETED","sponsor":"InnoRa GmbH","startDate":"2019-09-25","conditions":"Coronary Artery Disease","enrollment":70},{"nctId":"NCT01850108","phase":"NA","title":"Non-Myeloablative Conditioning and Bone Marrow Transplantation","status":"UNKNOWN","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2013-05","conditions":"Sickle Cell Disease, Hemoglobinopathies","enrollment":26},{"nctId":"NCT00518375","phase":"PHASE4","title":"Study Comparing Graft Function in Renal Allograft Recepients Receiving Reduced or Standard Dose CsA With Sirolimus","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2000-04","conditions":"Kidney Transplantation","enrollment":250},{"nctId":"NCT00519116","phase":"PHASE4","title":"Study Comparing Standard Dose and Reduced Dose Tacrolimus With Sirolimus in Renal Transplant Patients","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2000-10","conditions":"Kidney Transplantation","enrollment":150},{"nctId":"NCT04240444","phase":"NA","title":"Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis","status":"COMPLETED","sponsor":"B. Braun Medical International Trading Company Ltd.","startDate":"2020-10-10","conditions":"Coronary Artery Disease, In Stent Restenosis","enrollment":260},{"nctId":"NCT06066450","phase":"","title":"Efficacy of OSFIT Drug-Eluting Stent in Coronary Ostial Artery Stenosis","status":"RECRUITING","sponsor":"Genoss Co., Ltd.","startDate":"2023-07-07","conditions":"Drug-eluting Stent, Coronary Artery Disease","enrollment":1000},{"nctId":"NCT02110069","phase":"PHASE2","title":"A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors","status":"TERMINATED","sponsor":"Boston Children's Hospital","startDate":"2017-06-14","conditions":"Kaposiform Hemangioendothelioma (KHE), Kasabach-Merritt Syndrome, Tufted Angioma","enrollment":4},{"nctId":"NCT01517243","phase":"PHASE2","title":"Phase II Study of Alternating Sunitinib and Temsirolimus","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2010-09-22","conditions":"Metastatic Renal Cell Carcinoma","enrollment":37},{"nctId":"NCT01265030","phase":"PHASE1, PHASE2","title":"A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis","status":"COMPLETED","sponsor":"MaineHealth","startDate":"2014-02","conditions":"Desmoid Tumor","enrollment":9},{"nctId":"NCT04993872","phase":"PHASE4","title":"Pharmacokinetics of Calcineurin & mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF","status":"UNKNOWN","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2022-09-29","conditions":"HIV-infected Patient Kidney Transplant Recipient","enrollment":5},{"nctId":"NCT03797196","phase":"PHASE4","title":"RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2019-07-29","conditions":"Renal Transplant Recipients, Elderly Patients, Immunosuppression","enrollment":374},{"nctId":"NCT02385279","phase":"NA","title":"Study Comparing the MiStent SES Versus the XIENCE EES Stent","status":"COMPLETED","sponsor":"ECRI bv","startDate":"2015-03-20","conditions":"Coronary Stenosis","enrollment":1398},{"nctId":"NCT05780359","phase":"NA","title":"Evaluating the Safety and Efficacy of the G-stream® Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery","status":"RECRUITING","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2022-05-27","conditions":"Peripheral Artery Disease","enrollment":280},{"nctId":"NCT02042326","phase":"PHASE2","title":"Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2014-09-12","conditions":"Arteriovenous Malformations","enrollment":50},{"nctId":"NCT00406393","phase":"PHASE3","title":"Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2006-11","conditions":"Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Chronic","enrollment":304},{"nctId":"NCT02909335","phase":"PHASE3","title":"De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study","status":"WITHDRAWN","sponsor":"Rennes University Hospital","startDate":"2016-11","conditions":"Liver Transplantation","enrollment":""},{"nctId":"NCT02939365","phase":"PHASE4","title":"Precision Medicine Offers Belatacept Monotherapy","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2019-02","conditions":"Transplantation","enrollment":""},{"nctId":"NCT01976390","phase":"NA","title":"Comparing Everolimus and Sirolimus in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2013-10-01","conditions":"Renal Failure","enrollment":60},{"nctId":"NCT01935128","phase":"PHASE4","title":"Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction","status":"COMPLETED","sponsor":"University of Toledo Health Science Campus","startDate":"2013-07-03","conditions":"Renal Transplant","enrollment":55},{"nctId":"NCT02821026","phase":"PHASE1, PHASE2","title":"Omental Islet Transplant","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2016-05","conditions":"Type 1 Diabetes","enrollment":4},{"nctId":"NCT04323033","phase":"NA","title":"Safety and Efficacy of Peripheral, Cobalt-chromium Sirolimus Eluting Stent (PERS) Versus Cobalt-chromium Stent (Neptune C)","status":"COMPLETED","sponsor":"Balton Sp.zo.o.","startDate":"2019-03-13","conditions":"Peripheral Arterial Disease","enrollment":40},{"nctId":"NCT02806947","phase":"PHASE2","title":"A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2016-10","conditions":"Acute GVHD","enrollment":127},{"nctId":"NCT00789308","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07-11","conditions":"Diabetes Mellitus, Type I","enrollment":24},{"nctId":"NCT03525834","phase":"PHASE4","title":"Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-09","conditions":"Renal Angiomyolipoma","enrollment":40},{"nctId":"NCT02451696","phase":"PHASE2","title":"A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2014-01","conditions":"Epilepsy, Tuberous Sclerosis Complex, Focal Cortical Dysplasia","enrollment":15},{"nctId":"NCT04017364","phase":"NA","title":"Treatment of Coronary De-novo Stenosis by a Sirolimus Coated Balloon or a Paclitaxel Coated Balloon Catheter Malaysia","status":"COMPLETED","sponsor":"InnoRa GmbH","startDate":"2019-07-01","conditions":"Coronary Artery Disease","enrollment":70},{"nctId":"NCT03242096","phase":"NA","title":"Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated or a Paclitaxel Coated Balloon","status":"COMPLETED","sponsor":"InnoRa GmbH","startDate":"2017-07-21","conditions":"Coronary Restenosis","enrollment":50},{"nctId":"NCT01784861","phase":"PHASE1, PHASE2","title":"VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2013-05-03","conditions":"Adenocarcinoma, Pancreatic Neoplasms","enrollment":23},{"nctId":"NCT01445548","phase":"PHASE1, PHASE2","title":"Sirolimus for Advanced Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2011-09","conditions":"Age-Related Macular Degeneration, Geographic Atrophy","enrollment":6},{"nctId":"NCT01275222","phase":"PHASE1, PHASE2","title":"Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2002-11-13","conditions":"Gastrointestinal Stromal Tumors","enrollment":117},{"nctId":"NCT02137239","phase":"PHASE2","title":"Regimen Optimization Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-12-31","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT02009332","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Aadi Bioscience, Inc.","startDate":"2014-04-09","conditions":"Non-muscle Invasive Bladder Cancer (NMIBC)","enrollment":21},{"nctId":"NCT00702052","phase":"PHASE2","title":"Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-08-22","conditions":"Lymphoma, Mantle- Cell","enrollment":58},{"nctId":"NCT00426517","phase":"EARLY_PHASE1","title":"Donor Stem Cell Transplantation for Congenital Immunodeficiencies","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-01-19","conditions":"Inherited Immune Deficiencies","enrollment":48},{"nctId":"NCT01827943","phase":"PHASE2","title":"Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2009-06","conditions":"Relapsed Bladder Cancer","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rapamune® (Sirolimus)","genericName":"Rapamune® (Sirolimus)","companyName":"Wyeth is now a wholly owned subsidiary of Pfizer","companyId":"wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sirolimus inhibits mTOR (mammalian target of rapamycin), a key signaling protein that controls cell growth and proliferation, thereby suppressing immune cell activation and reducing organ rejection. Used for Prophylaxis of organ rejection in patients receiving renal transplants, Lymphangioleiomyomatosis (LAM).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}